Filtern
Volltext vorhanden
- ja (146)
Gehört zur Bibliographie
- ja (146)
Erscheinungsjahr
Dokumenttyp
- Artikel / Aufsatz in einer Zeitschrift (146) (entfernen)
Sprache
- Englisch (146) (entfernen)
Schlagworte
- Neurobiologie (38)
- Medizin (9)
- glioblastoma (8)
- astrocytoma (5)
- glioblastoma multiforme (5)
- Durchblutung (4)
- Gehirn (4)
- active zone (4)
- brain (4)
- deep brain stimulation (4)
- rats (4)
- recurrence (4)
- therapy (4)
- vestibular schwannoma (4)
- Glioblastoma (3)
- Hypothalamus (3)
- Parkinson's disease (3)
- Prostaglandine (3)
- TRH (3)
- blood pressure (3)
- brain tumor (3)
- mRNA (3)
- meningioma (3)
- metabolism (3)
- mice (3)
- neuroprotection (3)
- protein (3)
- relapse (3)
- subthalamic nucleus (3)
- traumatic brain injury (3)
- CNS disorders (2)
- COVID-19 (2)
- MPS1 (2)
- Mesenteric circulation (2)
- Neurophysiologie (2)
- Parkinson’s disease (2)
- SAH (2)
- Tumor Treating Fields (TTFields) (2)
- blood-brain barrier (2)
- blood–brain barrier (2)
- cancer stem cells (2)
- cardiac output (2)
- closed head injury (2)
- contact-kinin system (2)
- depression (2)
- dopamine (2)
- expression (2)
- factor XII (2)
- fluoroscopy (2)
- glioma (2)
- heart rate (2)
- imaging (2)
- inflammation (2)
- intraoperative imaging (2)
- local field potentials (2)
- low-grade glioma (2)
- mRNA expression (2)
- organoids (2)
- pathogenesis (2)
- radiotherapy (2)
- temozolomide (2)
- tumor necrosis factor (2)
- 2 PM (1)
- 2-photon microscopy (1)
- 3 D rotational fluoroscopy (1)
- 3D ex vivo models (1)
- 3D fluoroscopy (1)
- 3D in vitro model (1)
- ADAM9 (1)
- Anaphylactic shock (1)
- Anaphylaxis (1)
- Astrocytic tumor (1)
- Autoradiography (1)
- Axonal degeneration (1)
- BN 52021 (1)
- Bevacizumab (1)
- Biowissenschaften (1)
- Blood–brain barrier (1)
- Blutdruck (1)
- Bone chips (1)
- Brain stem (1)
- Bruchpilot (1)
- C1-inhibitor (1)
- CA2+ channels (1)
- CA3 (1)
- CA3 pyrimidal cells (1)
- CBF (1)
- CD133 (1)
- CNS cancer (1)
- CNS diseases (1)
- CRPS (1)
- CSVD (1)
- CX3CL1 (1)
- CXCL13 (1)
- CXCR4 (1)
- Cardiovascular (1)
- Cardiovascular system (1)
- Cerebral Ischemia (1)
- Cerebral-ischemia (1)
- Cranial window (1)
- Crespi effect (1)
- DBS biomarkers (1)
- DBS programming (1)
- Delayed cerebral infarction (1)
- Delayed ischemic neurological deficit (1)
- Drosophila melanogaster (1)
- E-cadherin (1)
- ED2 (1)
- Endothelium (1)
- Endothelzelle (1)
- Expression (1)
- Fibrin glue (1)
- Fluorescence (1)
- Glioblastom (1)
- Glioblastoma cell line (1)
- Glioblastoma multiforme (1)
- Glioblastomas (1)
- Glioma stem cells (1)
- HBO (1)
- HERV-K (1)
- Head-injury (1)
- Hemodynamic depression (1)
- Hemorrhage (1)
- Human endogenous retrovirus (1)
- IBA-1 (1)
- IDH (1)
- IDH1/2 (1)
- IL-6 (1)
- ISBI (1)
- Icosanoid (1)
- Immunostimulatory adjuvant (1)
- Immunotherapy (1)
- In vitro models (1)
- In vivo imaging (1)
- In-vivo dia lysis (1)
- IntelliCage (1)
- Intravascular coagulation (1)
- Intravital imaging (1)
- Irradiation (1)
- KIF (1)
- KIF11 (1)
- Lateral suboccipital craniectomy (1)
- Lipopolysaccharide (1)
- Lipoxin (1)
- Locus coeruleus (1)
- MGMT (1)
- MGMT promoter methylation (1)
- MMP9 (1)
- Merlin (1)
- Metalloproteinasen (1)
- Metastatic breast cancer (1)
- Mice (1)
- Microinjection (1)
- Model (1)
- Molecular-weight heparin (1)
- Mouse model (1)
- N-Acetyl-leukotriene E4 (1)
- NADPH oxidases (NOX) (1)
- NCH93 (1)
- NF2-related schwannomatosis (NF2) (1)
- Nestin (1)
- Neurons (1)
- Neuropeptides (1)
- Neuroprotection (1)
- Oncolysis (1)
- Osteogeneration (1)
- Osteopontin (1)
- PAF-acether (1)
- PCDHGC3 (1)
- PCR analysis (1)
- PDH (1)
- PET (1)
- PET/CT (1)
- PFA in ethanol (1)
- Pentixafor (1)
- Peptide-leukotrienes (1)
- Phase II trials (1)
- Physiologie (1)
- Prostaglandins (1)
- R-715 (1)
- RECK (1)
- RIM-binding protein (1)
- RIM1α (1)
- RS-13 (1)
- Rat hippocampus (1)
- Rats (1)
- Renal circulation (1)
- SARS-CoV-2 (1)
- SHRSP (1)
- SOAT1 (1)
- SV pool (1)
- Silver degeneration staining (1)
- Spinal dissemination (1)
- Staphylococcus (1)
- Subarachnoid hemorrhage (1)
- Supraoptic nucleus (1)
- Surgery (1)
- Sympathetic nervous system (1)
- T-2 toxin (1)
- TBI (1)
- TNF-α (1)
- TSPO (1)
- TTFields (1)
- TTK (1)
- Temozolomide (1)
- Thromboplastin (1)
- Thrombus formation (1)
- Thyreotropin-Releasinghormon (1)
- Trauma (1)
- Tumor-Treating Fields (TTFields) (1)
- VLSM (1)
- Vasopressin (1)
- Ventilation (1)
- Von Willebrand factor (1)
- WNT signaling (1)
- Willebrand-Faktor (1)
- Zell-Adhäsionsmolekül (1)
- [3H][3Me-His2]-TRH (1)
- \(^{68}\)Ga-Pentixafor (1)
- accelerator based radiosurgery (1)
- acoustic startle (1)
- acute brain slices (1)
- adherence (1)
- adolescence (1)
- aerobic glycolysis (1)
- aging (1)
- alkaline phosphatase (1)
- amplitude criterion (1)
- amyloidoma (1)
- anaplastic medulloblastoma (1)
- aneurysm (1)
- animal model (1)
- anticancer activity (1)
- anxiety (1)
- asfotase alfa (1)
- astrocytes (1)
- astrocytic tumor (1)
- astroglia (1)
- atrial fibrillation (1)
- audiometry (1)
- autoradiography (1)
- behavior (1)
- benzodiazepine antagonist. (1)
- beta oscillations (1)
- beta power (1)
- beta-catenin (1)
- blastocysts (1)
- blood brain barrier (1)
- blood nerve barrier (1)
- blood-brain-barrier (1)
- bradykinin (1)
- brain development (1)
- brain edema (1)
- brain-injury (1)
- brainstem auditory evoked potentials (1)
- cancer (1)
- catecholamlnes (1)
- cerebEND (1)
- cerebEND cells (1)
- cerebraI ischemia (1)
- cerebrovascular disorders (1)
- cervical spine (1)
- chemokine receptor-4 (1)
- chemotherapy (1)
- childhood (1)
- children (1)
- chlorisondamine (1)
- chronic heart failure (1)
- chronic stimulation (1)
- claudin-1 (1)
- clinical trials (1)
- cognitive function (1)
- cognitive functions (1)
- coherence analysis (1)
- compaction (1)
- craniofacial orthodontics (1)
- craniovertebral junction (1)
- cytokines (1)
- dSTORM (1)
- damage control orthopedics (1)
- deafness (1)
- deformational cranial asymmetry (1)
- dennorphin (1)
- derivation (1)
- dermorphin (1)
- dexamethasone (1)
- differentiation (1)
- diffuse (1)
- diffuse astrocytoma (1)
- direct cortical stimulation (1)
- directional deep brain stimulation (1)
- distress (1)
- double-blind (1)
- early brain injury (1)
- edema (1)
- electron tomography (1)
- executive function (1)
- experimental stroke (1)
- expression pattern (1)
- femoral fracture (1)
- flumazenil (1)
- focal (1)
- focal brain lesion (1)
- focal cerebral-ischemia (1)
- frameless systems (1)
- gamma knife radiosurgery (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (GBM) (1)
- glucocorticoid receptor (1)
- group 3 (1)
- guidelines (1)
- head (1)
- hearing preservation (1)
- hemorrhagic shock (1)
- high-pressure freezing (1)
- high-pressure freezing/freeze substitution (1)
- hippocampal (1)
- hippocampal mossy fiber bouton (1)
- homeostasis (1)
- human brain microvascular endothelial cells (HBMVEC) (1)
- human cells (1)
- hypophosphatasia (1)
- hypovolemic hypotension (1)
- hypoxia (1)
- image-guided programming (1)
- immunofluorescence (1)
- immunofuorescence double staining (1)
- immunohistochemistry (1)
- in vitro model (1)
- in vivo (1)
- in-vitro (1)
- in-vivo (1)
- infants with deformational plagiocephaly (DP) (1)
- inflammatory mechanisms (1)
- integrin (1)
- internalized stigmatization (1)
- intraoperative monitoring (1)
- ischemia (1)
- isosteviol sodium (1)
- isosteviol sodium (STVNA) (1)
- kallikrein–kinin system (1)
- kinesin (1)
- kinin receptor (1)
- kinin receptors (1)
- knock down (1)
- lesion symptom mapping (1)
- lines (1)
- lipid droplets (1)
- liponeurocytoma (1)
- lipopolysaccharides (1)
- liquid biopsy (1)
- locus coeruleus (1)
- lower grade glioma (1)
- macrophages (1)
- management (1)
- matrix metalloproteinase (1)
- mechanism of action (1)
- medulloblastoma (1)
- memory (1)
- metastasis (1)
- metastasis associated in colorectal cancer 1 (MACC1) (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- methylprednisolone (1)
- microRNA (1)
- microglia (1)
- minimally invasive (1)
- minocycline (1)
- mitotane (1)
- modulation (1)
- molecular imaging (1)
- molecular signature (1)
- mononuclear phagocytes (1)
- mortality (1)
- mossy fiber synapses (1)
- motor control (1)
- mouse-brain (1)
- movement (1)
- movement disorders (1)
- multifocal growth (1)
- multiple sclerosis (1)
- mycotoxin (1)
- myocardial infarction (1)
- naloxonazine (1)
- naloxone (1)
- nanotopology (1)
- nausea and emesis (1)
- nervous-sytem (1)
- neural stem-cells (1)
- neurocytoma (1)
- neurodegenerative disease (1)
- neurofibromatosis type 2 (1)
- neuroinflammation (1)
- neurological complications (1)
- neurology (1)
- neuromuscular junction (1)
- neuronal damage (1)
- neuronavigation (1)
- neurooncology (1)
- neuropathic pain (1)
- neurosurgery (1)
- neurovascular disorders (1)
- neurovascular unit (1)
- non-VKA oral anticoagulants (1)
- non-small cell lung cancer (NSCLC) (1)
- nucleus (1)
- object recognition memory (1)
- obsessive-compulsive disorder (1)
- occupation (1)
- oligodendroglioma (1)
- opiates (1)
- opioid peptides (1)
- opioid receptors (1)
- opioid-benzodiazepine interactions (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- orthotopic xenograft (1)
- osteomalacia (1)
- ovarian cancer (1)
- oxidative stress (1)
- paediatric cancer (1)
- pain (1)
- palladium (1)
- pancreatic cancer (1)
- paragangliomas (1)
- pedicle screws (1)
- peptide receptor radionuclide therapy (PRRT) (1)
- physical examination (1)
- plasticity (1)
- platelet activating factor (1)
- platelet-activating factor (1)
- platform (1)
- platinum (1)
- pluripotent (1)
- positionalskull deformities (1)
- positron emission tomography/computed tomography (1)
- presynaptic (1)
- presynaptic plasticity (1)
- prevention (1)
- primary cell culture (1)
- progenitors (1)
- prognostic marker (1)
- prostacyclins (1)
- proteins (1)
- psychiatric disorders (1)
- pyramidal neurons (1)
- quality of life (1)
- radiation therapy (1)
- randomized controlled double-blind study (1)
- rare bone disease (1)
- rat (1)
- recombinat-human-erythropoietin (1)
- reflex (1)
- regional blood flow (1)
- regional blood ftow (1)
- release (1)
- renin (1)
- resilience (1)
- resistance (1)
- respiration (1)
- reveals (1)
- rickets (1)
- scale (1)
- schizophrenia (1)
- secondary brain damage (1)
- senescence (1)
- serotonin (1)
- shock (1)
- skull base (1)
- slice culture (1)
- specification (1)
- spinal tumor operation (1)
- spine (1)
- stereotaxy (1)
- stress (1)
- stroke (1)
- stroke therapy (1)
- subarachnoid hemorrhage (1)
- subarachnoid hemorrhage (SAH) (1)
- subjective perception (1)
- super-resolution microscopy (1)
- suppressor (1)
- surgery (1)
- sympathetic nerve activity. (1)
- synaptic ultrastructure (1)
- tPA (1)
- targeted therapy (1)
- taxanes (1)
- temporal bone (1)
- therapy response (1)
- thiosemicarbazone (1)
- three-dimensional (1)
- three-dimensional imaging (1)
- threshold criterion (1)
- threshold level (1)
- thromboinflammation (1)
- thrombosis (1)
- total peripheral resistance (1)
- transcranial motor-evoked potentials (1)
- transient ischemic attack (1)
- tumor slice cultures (1)
- tumor-necrosis-factor (1)
- tumormicroenvironment (1)
- vasopressin (1)
- vertebral pedicles (1)
- vitamin K antagonists (1)
- warfarin (1)
- weight drop (1)
- µ opioid receptors (1)
- µ·Opioid receptor subtypes (1)
- β-APP (1)
Institut
- Neurochirurgische Klinik und Poliklinik (146) (entfernen)
Current data show that resilience is an important factor in cancer patients’ well-being. We aim to explore the resilience of patients with lower grade glioma (LGG) and the potentially influencing factors. We performed a cross-sectional assessment of adult patients with LGG who were enrolled in the LoG-Glio registry. By phone interview, we administered the following measures: Resilience Scale (RS-13), distress thermometer, Montreal Cognitive Assessment Test for visually impaired patients (MoCA-Blind), internalized stigmatization by brain tumor (ISBI), Eastern Cooperative Oncological Group performance status (ECOG), patients’ perspective questionnaire (PPQ) and typical clinical parameters. We calculated correlations and multivariate regression models. Of 74 patients who were assessed, 38% of those showed a low level of resilience. Our results revealed significant correlations of resilience with distress (p < 0.001, −0.49), MOCA (p = 0.003, 0.342), ECOG (p < 0.001, −0.602), stigmatization (p < 0.001, −0.558), pain (p < 0.001, −0.524), and occupation (p = 0.007, 0.329). In multivariate analyses, resilience was negatively associated with elevated ECOG (p = 0.020, β = −0.383) and stigmatization levels (p = 0.008, β = −0.350). Occupation showed a tendency towards a significant association with resilience (p = 0.088, β = −0.254). Overall, low resilience affected more than one third of our cohort. Low functional status is a specific risk factor for low resilience. The relevant influence of stigmatization on resilience is a novel finding for patients suffering from a glioma and should be routinely identified and targeted in clinical routine.
Early treatment with glucocorticoids could help reduce both cytotoxic and vasogenic edema, leading to improved clinical outcome after stroke. In our previous study, isosteviol sodium (STVNA) demonstrated neuroprotective effects in an in vitro stroke model, which utilizes oxygen-glucose deprivation (OGD). Herein, we tested the hypothesis that STVNA can activate glucocorticoid receptor (GR) transcriptional activity in brain microvascular endothelial cells (BMECs) as previously published for T cells. STVNA exhibited no effects on transcriptional activation of the glucocorticoid receptor, contrary to previous reports in Jurkat cells. However, similar to dexamethasone, STVNA inhibited inflammatory marker IL-6 as well as granulocyte-macrophage colony-stimulating factor (GM-CSF) secretion. Based on these results, STVNA proves to be beneficial as a possible prevention and treatment modality for brain ischemia-reperfusion injury-induced blood–brain barrier (BBB) dysfunction.
Despite the availability of numerous therapeutic substances that could potentially target CNS disorders, an inability of these agents to cross the restrictive blood–brain barrier (BBB) limits their clinical utility. Novel strategies to overcome the BBB are therefore needed to improve drug delivery. We report, for the first time, how Tumor Treating Fields (TTFields), approved for glioblastoma (GBM), affect the BBB’s integrity and permeability. Here, we treated murine microvascular cerebellar endothelial cells (cerebEND) with 100–300 kHz TTFields for up to 72 h and analyzed the expression of barrier proteins by immunofluorescence staining and Western blot. In vivo, compounds normally unable to cross the BBB were traced in healthy rat brain following TTFields administration at 100 kHz. The effects were analyzed via MRI and immunohistochemical staining of tight-junction proteins. Furthermore, GBM tumor-bearing rats were treated with paclitaxel (PTX), a chemotherapeutic normally restricted by the BBB combined with TTFields at 100 kHz. The tumor volume was reduced with TTFields plus PTX, relative to either treatment alone. In vitro, we demonstrate that TTFields transiently disrupted BBB function at 100 kHz through a Rho kinase-mediated tight junction claudin-5 phosphorylation pathway. Altogether, if translated into clinical use, TTFields could represent a novel CNS drug delivery strategy.
Glioblastoma leads to a fatal course within two years in more than two thirds of patients. An essential cornerstone of therapy is chemotherapy with temozolomide (TMZ). The effect of TMZ is counteracted by the cellular repair enzyme O\(^6\)-methylguanine-DNA methyltransferase (MGMT). The MGMT promoter methylation, the main regulator of MGMT expression, can change from primary tumor to recurrence, and TMZ may play a significant role in this process. To identify the potential mechanisms involved, three primary stem-like cell lines (one astrocytoma with the mutation of the isocitrate dehydrogenase (IDH), CNS WHO grade 4 (HGA)), and two glioblastoma (IDH-wildtype, CNS WHO grade 4) were treated with TMZ. The MGMT promoter methylation, migration, proliferation, and TMZ-response of the tumor cells were examined at different time points. The strong effects of TMZ treatment on the MGMT methylated cells were observed. Furthermore, TMZ led to a loss of the MGMT promoter hypermethylation and induced migratory rather than proliferative behavior. Cells with the unmethylated MGMT promoter showed more aggressive behavior after treatment, while HGA cells reacted heterogenously. Our study provides further evidence to consider the potential adverse effects of TMZ chemotherapy and a rationale for investigating potential relationships between TMZ treatment and change in the MGMT promoter methylation during relapse.
Ten thiosemicarbazone ligands obtained by condensation of pyridine-2-carbaldehyde, quinoline-2-carbaldehyde, 2-acetylpyridine, 2-acetylquinoline, or corresponding 2-pyridyl ketones with thiosemicarbazides RNHC(S)NHNH\(_{2}\) and R=CH\(_{3}\), C\(_{6}\)H\(_{5}\) were prepared in good yield. The reaction of [PdCl\(_{2}\)(cod)] with cod=1,5-cyclooctadiene or K\(_{2}\)[PtCl\(_{4}\)] resulted in a total of 17 Pd(II) and Pt(II) complexes isolated in excellent purity, as demonstrated by \(^{1}\)H, \(^{13}\)C, and, where applicable, \(^{195\)Pt NMR spectroscopy combined with CHNS analysis. The cytotoxicity of the title compounds was studied on four human glioblastoma cell lines (GaMG, U87, U138, and U343). The most active compound, with a Pd(II) metal centre, a 2-quinolinyl ring, and methyl groups on both the proximal C and distal N atoms exhibited an EC\(_{50}\) value of 2.1 μM on the GaMG cell lines, thus being slightly more active than cisplatin (EC\(_{50}\) 3.4 μM) and significantly more potent than temozolomide (EC\(_{50}\) 67.1 μM). Surprisingly, the EC\(_{50}\) values were inversely correlated with the lipophilicity, as determined with the “shake-flask method”, and decreased with the length of the alkyl substituents (C\(_{1}\)>C\(_{8}\)>C\(_{10}\)). Correlation with the different structural motifs showed that for the most promising anticancer activity, a maximum of two aromatic rings (either quinolinyl or pyridyl plus phenyl) combined with one methyl group are favoured and the Pd(II) complexes are slightly more potent than their Pt(II) analogues.
Both nerve injury and complex regional pain syndrome (CRPS) can result in chronic pain. In traumatic neuropathy, the blood nerve barrier (BNB) shielding the nerve is impaired—partly due to dysregulated microRNAs (miRNAs). Upregulation of microRNA-21-5p (miR-21) has previously been documented in neuropathic pain, predominantly due to its proinflammatory features. However, little is known about other functions. Here, we characterized miR-21 in neuropathic pain and its impact on the BNB in a human-murine back translational approach. MiR-21 expression was elevated in plasma of patients with CRPS as well as in nerves of mice after transient and persistent nerve injury. Mice presented with BNB leakage, as well as loss of claudin-1 in both injured and spared nerves. Moreover, the putative miR-21 target RECK was decreased and downstream Mmp9 upregulated, as was Tgfb. In vitro experiments in human epithelial cells confirmed a downregulation of CLDN1 by miR-21 mimics via inhibition of the RECK/MMP9 pathway but not TGFB. Perineurial miR-21 mimic application in mice elicited mechanical hypersensitivity, while local inhibition of miR-21 after nerve injury reversed it. In summary, the data support a novel role for miR-21, independent of prior inflammation, in elicitation of pain and impairment of the BNB via RECK/MMP9.
Based on recent findings that show that depletion of factor XII (FXII) leads to better posttraumatic neurological recovery, we studied the effect of FXII-deficiency on post-traumatic cognitive and behavioral outcomes in female and male mice. In agreement with our previous findings, neurological deficits on day 7 after weight-drop traumatic brain injury (TBI) were significantly reduced in FXII\(^{−/−}\) mice compared to wild type (WT) mice. Also, glycoprotein Ib (GPIb)-positive platelet aggregates were more frequent in brain microvasculature of WT than FXII\(^{−/−}\) mice 3 months after TBI. Six weeks after TBI, memory for novel object was significantly reduced in both female and male WT but not in FXII\(^{−/−}\) mice compared to sham-operated mice. In the setting of automated home-cage monitoring of socially housed mice in IntelliCages, female WT mice but not FXII\(^{−/−}\) mice showed decreased exploration and reacted negatively to reward extinction one month after TBI. Since neuroendocrine stress after TBI might contribute to trauma-induced cognitive dysfunction and negative emotional contrast reactions, we measured peripheral corticosterone levels and the ration of heart, lung, and spleen weight to bodyweight. Three months after TBI, plasma corticosterone levels were significantly suppressed in both female and male WT but not in FXII\(^{−/−}\) mice, while the relative heart weight increased in males but not in females of both phenotypes when compared to sham-operated mice. Our results indicate that FXII deficiency is associated with efficient post-traumatic behavioral and neuroendocrine recovery.
Positional plagiocephaly (PP) is the most common skull deformity in infants. Different classification systems exist for graduating the degree of PP, but all of these systems are based on two-dimensional (2D) parameters. This limitation leads to several problems stemming from the fact that 2D parameters are used to classify the three-dimensional (3D) shape of the head. We therefore evaluate existing measurement parameters and validate a newly developed 3D parameter for quantifying PP. Additionally, we present a new classification of PP based on a 3D parameter. 210 patients with PP and 50 patients without PP were included in this study. Existing parameters (2D and 3D) and newly developed volume parameters based on a 3D stereophotogrammetry scan were validated using ROC curves. Additionally, thresholds for the new 3D parameter of a 3D asymmetry index were assessed. The volume parameter 3D asymmetry index quantifies PP equally as well as the gold standard of 30° diagonal difference. Moreover, a 3D asymmetry index allows for a 3D-based classification of PP. The 3D asymmetry index can be used to define the degree of PP. It is easily applicable in stereophotogrammetric datasets and allows for comparability both intra- and inter-individually as well as for scientific analysis.
Ultrastructural analysis of wild-type and RIM1α knockout active zones in a large cortical synapse
(2022)
Rab3A-interacting molecule (RIM) is crucial for fast Ca\(^{2+}\)-triggered synaptic vesicle (SV) release in presynaptic active zones (AZs). We investigated hippocampal giant mossy fiber bouton (MFB) AZ architecture in 3D using electron tomography of rapid cryo-immobilized acute brain slices in RIM1α\(^{−/−}\) and wild-type mice. In RIM1α\(^{−/−}\), AZs are larger with increased synaptic cleft widths and a 3-fold reduced number of tightly docked SVs (0–2 nm). The distance of tightly docked SVs to the AZ center is increased from 110 to 195 nm, and the width of their electron-dense material between outer SV membrane and AZ membrane is reduced. Furthermore, the SV pool in RIM1α\(^{−/−}\) is more heterogeneous. Thus, RIM1α, besides its role in tight SV docking, is crucial for synaptic architecture and vesicle pool organization in MFBs.
Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma
(2022)
Background
Despite of a multimodal approach, recurrences can hardly be prevented in glioblastoma. This may be in part due to so called glioma stem cells. However, there is no established marker to identify these stem cells.
Methods
Paired samples from glioma patients were analyzed by immunohistochemistry for expression of the following stem cell markers: CD133, Musashi, Nanog, Nestin, octamer-binding transcription factor 4 (Oct4), and sex determining region Y-box 2 (Sox2). In addition, the expression of osteopontin (OPN) was investigated. The relative number of positively stained cells was determined. By means of Kaplan–Meier analysis, a possible association with overall survival by marker expression was investigated.
Results
Sixty tissue samples from 30 patients (17 male, 13 female) were available for analysis. For Nestin, Musashi and OPN a significant increase was seen. There was also an increase (not significant) for CD133 and Oct4. Patients with mutated Isocitrate Dehydrogenase-1/2 (IDH-1/2) status had a reduced expression for CD133 and Nestin in their recurrent tumors. Significant correlations were seen for CD133 and Nanog between OPN in the primary and recurrent tumor and between CD133 and Nestin in recurrent tumors. By confocal imaging we could demonstrate a co-expression of CD133 and Nestin within recurrent glioma cells. Patients with high CD133 expression had a worse prognosis (22.6 vs 41.1 months, p = 0.013). A similar trend was seen for elevated Nestin levels (24.9 vs 41.1 months, p = 0.08).
Conclusions
Most of the evaluated markers showed an increased expression in their recurrent tumor. CD133 and Nestin were associated with survival and are candidate markers for further clinical investigation.